An observational study in Neoplasms, Oncology Service and Health Services Accessibility, sponsored by Centre Hospitalier de Saint-Denis. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Centre Hospitalier de Saint-Denis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. The goal is to better understand inequalities in access to care and to improve patient support in the future.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 300 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Hospitalier de Saint-Denis is the lead sponsor of 46 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study participants will be selected from the population of patients treated for cancer in the oncology department of Delafontaine Hospital, located in Seine-Saint-Denis (93), France. This population includes adult patients receiving chemotherapy, radiotherapy, targeted therapies, immunotherapy, or supportive care as part of their cancer management. Since Delafontaine Hospital is a public hospital in a densely populated and socioeconomically diverse area of the Paris region, the patient population is expected to reflect a wide range of social, cultural, and economic backgrounds, including a high proportion of individuals from immigrant communities. This diversity provides a valuable context for studying inequalities in geographic accessibility to oncology care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adult patients treated for cancer in the oncology department of Delafontaine Hospital since January 1, 2020.
Exclusion Criteria:
- Patients whose cancer treatment in the oncology department was completed before 2020.
Median travel time (minutes) from the patient's place of residence (IRIS centroid) to Delafontaine Hospital by the patient's usual mode of transport for oncology appointments.
Time frame: Assessed up to 5 years after first inclusion
Start is estimated for Oct 2025; primary completion for Apr 2026, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Saint-Denis